84388-68-1

Basic information

• Product Name: 4,5-Dichlorosalicylaldehyde
• Synonyms: 4,5-Dichlorosalicylaldehyde
• CAS NO: 84388-68-1
• Molecular Formula: C₇H₄Cl₂O₂
• Molecular Weight: 191.01146
• Mol File: 84388-68-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4,5-Dichlorosalicylaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-Dichlorosalicylaldehyde(84388-68-1)
• EPA Substance Registry System: 4,5-Dichlorosalicylaldehyde(84388-68-1)

Safety Data

• Hazardous Substances Data: 84388-68-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,5-Dichlorosalicylaldehyde is used as a building block for the preparation of various pharmaceuticals, due to its versatile chemical properties and reactivity.
Used in Agrochemical Industry:
4,5-Dichlorosalicylaldehyde is used as a precursor in the synthesis of agrochemicals, contributing to the development of effective crop protection agents.
Used in Dye Industry:
4,5-Dichlorosalicylaldehyde is used in the production of dyes, taking advantage of its chemical structure to create a range of colorants for various applications.
Used in Synthesis of Heterocycles:
4,5-Dichlorosalicylaldehyde is used as a precursor in the synthesis of heterocycles, which are important in the development of complex organic molecules and have applications in various fields.
Used in Coordination Complexes and Metal-based Catalysts:
4,5-Dichlorosalicylaldehyde is used in the formation of coordination complexes and as ligands for metal-based catalysts, playing a crucial role in catalytic reactions.
Used in Fragrance and Flavor Industry:
4,5-Dichlorosalicylaldehyde is utilized in the production of fragrances and flavors, adding to the diversity of scents and tastes in various consumer products.
Used in Antimicrobial and Anticancer Agents Development:
4,5-Dichlorosalicylaldehyde is studied for its potential use in the development of materials with antimicrobial and anticancer properties, due to its chemical structure and reactivity.
Used in Analytical Chemistry:
4,5-Dichlorosalicylaldehyde has been studied for its potential use in analytical chemistry, particularly as a fluorescent probe for the detection of metal ions, enhancing the sensitivity and selectivity of analytical methods.

Upstream product

• 67-66-3 chloroform 
• 95-77-2 3,4-dichlorophenol 
• 100-97-0 hexamethylenetetramine 
• 75-75-2 methanesulfonic acid 
• 6287-38-3 3,4-dichlorobenzaldehyde 

Downstream Products

• 37420-52-3 1-(bromomethyl)-4,5-dichloro-2-methoxybenzene 
• 883532-73-8 4,5-dichloro-2-methoxybenzaldehyde 

Relevant articles and documents

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula I ( I ), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I), or a pharmaceutically-acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

ARYLMETHYLENE AROMATIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles

GPR40 has become a new potential therapeutic target for the treatment of diabetes due to its role in mediating the enhancement of glucose-stimulated insulin secretion in pancreatic β cells with a low risk of hypoglycemia. As an effort to extend the chemical space and identify structurally distinct GPR40 agonists with improved liver safety, a novel series of fused-ring phenyl propanoic acid analogues were designed. Comprehensive structure-activity relationship studies around novel scaffolds were conducted and led to several analogues exhibited potent GPR40 agonistic activities and high selectivity against other fatty acid receptors. Further evaluation of pharmacokinetic (PK) profiles and in vivo efficacy identified compound 40a with excellent PK properties and significant glucose-lowering efficacy during an oral glucose tolerance test. In addition, compound 40a displayed lower hepatobiliary transporter inhibition and favorable druggability. All results indicate that compound 40a is a promising candidate for further development.

Pd-Catalyzed Ortho C-H Hydroxylation of Benzaldehydes Using a Transient Directing Group

The direct Pd-catalyzed ortho C-H hydroxylation of benzaldehydes was achieved using 4-chloroanthranilic acid as the transient directing group, 1-fluoro-2,4,6-trimethylpyridnium triflate as the bystanding oxidant, and p-toluenesulfonic acid as the putative oxygen nucleophile. The unusual C-H chlorination and polyfluoroalkoxylation reactions signaled the importance of external nucleophiles to the outcome of Pd(IV) reductive eliminations.

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models

A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists. Compound (+)-22a was identified as a potent

CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS

Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.

BORONIC ACID BEARING LIPHAGANE COMPOUNDS AS INHIBITORS OF P13K- a AND/OR B

Compounds with unique liphagane meroterpenoid scaffold having boronic acid functionality in the skeleton are described (formula 1) together with pharmacological potential of these compounds as anticancer agents. A method of preparation and inhibiting the activity of phosphoinositide-3-kinase (PI3K-alpha and beta) has been presented. In particular, the invention describes a method of inhibiting PI3K isoforms, wherein the compounds are novel structures based on liphagane scaffold with unique boronic acid functionality. The methods and uses thereof are described herein this invention.

BORONIC ACID BEARING LIPHAGANE COMPOUNDS AS INHIBITORS OF PI3K-alpha AND/OR beta

Compounds with unique liphagane meroterpenoid scaffold having boronic acid functionality in the skeleton are described [formula 1] together with pharmacological potential of these compounds as anticancer agents. A method of preparation and inhibiting the activity of phosphoinositide-3-kinase (PI3K-alpha and beta) has been presented. In particular, the invention describes a method of inhibiting PI3K isoforms, wherein the compounds are novel structures based on liphagane scaffold with unique boronic acid functionality. The methods and uses thereof are described herein this invention. The claimed Markush formula is: [Formular 1], Y can be O, NH, NR, S; Representative compounds are: [Compounds A, B, C, D]

WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS

The present invention relates to compounds according to the structure (I): Where R is —CH3 or —CH2CH2Cl; R′ is C1-C7 alkyl or —CH2CH2Cl; R2 or R4 is OPOsub